Literature DB >> 2476498

HIV-1-specific B cell activation. A major constituent of spontaneous B cell activation during HIV-1 infection.

A Amadori1, R Zamarchi, V Ciminale, A Del Mistro, S Siervo, A Alberti, M Colombatti, L Chieco-Bianchi.   

Abstract

B cell activation is a well known consequence of HIV-1 infection, and seropositive subjects show high numbers of spontaneously activated Ig-secreting cells in circulation. To better define the importance of the HIV-1-specific response in this phenomenon, we first studied whether in vitro spontaneous anti-HIV-1 antibody production was accompanied by reactivation of memory B lymphocytes. Unstimulated PBL from HIV-1-infected individuals with prior history of hepatitis B and/or EBV infection did not consistently show spontaneous in vitro synthesis of anti-hepatitis B core Ag or anti-EBV antibodies; in addition, PWM-induced synthesis of anti-hepatitis B virus and anti-EBV antibodies was decreased compared to HIV-1-seronegative subjects. Moreover, in comparing the frequencies of activated HIV-1-specific B cell precursors and activated Ig-secreting precursors in limiting dilution experiments, a sizable fraction (20 to 40%) of circulating cells spontaneously secreting Ig produced antibody against HIV-1 determinants. The ratio between the two frequencies fitted in very well with the amount of Ig removed from unstimulated culture supernatants after HIV-1-specific antibody absorption with solid-phase HIV-1. These findings indicate that B cell activation during HIV-1 infection is mainly oriented toward a specific response to HIV-1 determinants; the possible relevance of this phenomenon to lymphomagenesis in AIDS patients is discussed.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2476498

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  40 in total

1.  A gp120 HIV peptide with high similarity to HLA class II beta chains enhances PPD-specific and autoreactive T cell activation.

Authors:  O Pugliese; M Viora; B Camponeschi; P Cordiali Fei; F Caprilli; A Chersi; M Evangelista; A M Di Massimo; V Colizzi
Journal:  Clin Exp Immunol       Date:  1992-11       Impact factor: 4.330

2.  Frequencies of HIV-reactive B cells in seropositive and seronegative individuals.

Authors:  R H Zubler; L H Perrin; A Doucet; X Zhang; Y P Huang; P A Miescher
Journal:  Clin Exp Immunol       Date:  1992-01       Impact factor: 4.330

3.  Molecular determinants of the human antibody response to HIV-1: implications for disease control.

Authors:  M Viau; M Zouali
Journal:  J Clin Immunol       Date:  2001-11       Impact factor: 8.317

4.  Alterations in peripheral blood B-cell populations in SHIV89.6P-infected macaques (Macacca fascicularis).

Authors:  Heather M Kling; Timothy W Shipley; Karen A Norris
Journal:  Comp Med       Date:  2011-06       Impact factor: 0.982

Review 5.  B cell responses to HIV and the development of human monoclonal antibodies.

Authors:  J E Boyd; K James
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

Review 6.  How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development?

Authors:  Per Johan Klasse; Rogier W Sanders; Andrea Cerutti; John P Moore
Journal:  AIDS Res Hum Retroviruses       Date:  2011-05-20       Impact factor: 2.205

7.  Serum levels of the chemokine CXCL13, genetic variation in CXCL13 and its receptor CXCR5, and HIV-associated non-hodgkin B-cell lymphoma risk.

Authors:  Shehnaz K Hussain; Weiming Zhu; Shen-Chih Chang; Elizabeth Crabb Breen; Elena Vendrame; Larry Magpantay; Dan Widney; Daniel Conn; Mary Sehl; Lisa P Jacobson; Jay H Bream; Steven Wolinsky; Charles R Rinaldo; Richard F Ambinder; Roger Detels; Zuo-Feng Zhang; Otoniel Martínez-Maza
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-12-18       Impact factor: 4.254

8.  Association of phenotypic changes in B cell lymphocytes and plasma viral load in human immunodeficiency virus-infected patients.

Authors:  M R Dawood; B Conway; P Patenaude; F Janmohamed; J S Montaner; M V O'Shaughnessy; G W Hammond
Journal:  J Clin Immunol       Date:  1998-05       Impact factor: 8.317

9.  Enhanced in vitro human immunodeficiency virus type 1 replication in B cells expressing surface antibody to the TM Env protein.

Authors:  Y Tani; E Donoghue; S Sharpe; E Boone; H C Lane; S Zolla-Pazner; D I Cohen
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

10.  Phenotypical and functional evaluation of CD8+/S6F1+ T lymphocytes in haemophiliac individuals with HIV-1 infection.

Authors:  F Cavallin; A Traldi; R Zambello
Journal:  Clin Exp Immunol       Date:  1993-07       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.